Using loop diuretics to improve same-day discharge after prostate surgery
Loop Diuretics During Morcellation to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
PHASE3 · Northwestern University · NCT05620784
This study is testing if giving a diuretic during prostate surgery can help men go home the same day by improving their recovery and reducing complications.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 138 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | Male |
| Sponsor | Northwestern University (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05620784 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of intra-operative administration of furosemide on same-day discharge rates following Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hypertrophy (BPH). Patients will be randomly assigned to receive either 20mg of IV furosemide or a control treatment during the procedure. The study aims to determine if the use of furosemide significantly affects post-operative urinary output and reduces complications such as hematuria, thereby facilitating same-day discharge. The trial is conducted at Northwestern University and involves male patients aged 18 to 89 undergoing HoLEP.
Who should consider this trial
Good fit: Ideal candidates are males aged 18 to 89 who are scheduled to undergo HoLEP for BPH.
Not a fit: Patients with allergies to furosemide, anuria, liver failure, or those undergoing concurrent surgeries may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance recovery protocols, allowing more patients to safely return home on the same day after surgery.
How similar studies have performed: While the use of furosemide in this context is common, this study is novel in its systematic evaluation of its effectiveness for same-day discharge rates.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males 18 -89 undergoing HoLEP * Willing to sign the Informed Consent Form * Able to read, understand, and complete patient questionnaires. Exclusion Criteria: * Allergy or hypersensitivity to furosemide or other loop diuretic * Anuric patients or patients with liver failure * Patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP * Anticipated need for perineal urethrostomy at the time of HoLEP * Patient not undergoing catheter removal and voiding trial at Northwestern Memorial Hospital
Where this trial is running
Chicago, Illinois
- Northwestern University — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Amy E Krambeck, MD — Northwestern Medicine
- Study coordinator: Nicholas S Dean, MD
- Email: nicholas.dean@northwestern.edu
- Phone: 7806906285
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge